Goldman Sachs Group Inc. cut its position in shares of Dexcom (NASDAQ:DXCM) by 15.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,553,874 shares of the medical device company’s stock after selling 283,667 shares during the period. Goldman Sachs Group Inc. owned approximately 1.79% of Dexcom worth $89,177,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its holdings in shares of Dexcom by 3.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock worth $12,967,000 after buying an additional 8,171 shares during the period. FDx Advisors Inc. boosted its position in Dexcom by 33.3% during the 4th quarter. FDx Advisors Inc. now owns 23,071 shares of the medical device company’s stock valued at $1,324,000 after acquiring an additional 5,764 shares in the last quarter. Swiss National Bank boosted its position in Dexcom by 3.4% during the 3rd quarter. Swiss National Bank now owns 318,400 shares of the medical device company’s stock valued at $15,578,000 after acquiring an additional 10,500 shares in the last quarter. Legal & General Group Plc boosted its position in Dexcom by 15.9% during the 3rd quarter. Legal & General Group Plc now owns 95,757 shares of the medical device company’s stock valued at $4,685,000 after acquiring an additional 13,166 shares in the last quarter. Finally, State of Wisconsin Investment Board boosted its position in Dexcom by 169.7% during the 3rd quarter. State of Wisconsin Investment Board now owns 184,765 shares of the medical device company’s stock valued at $9,040,000 after acquiring an additional 116,254 shares in the last quarter.
A number of analysts have recently weighed in on DXCM shares. Oppenheimer set a $67.00 price objective on Dexcom and gave the stock a “buy” rating in a research report on Monday, February 12th. Piper Jaffray set a $60.00 target price on Dexcom and gave the stock a “buy” rating in a research note on Monday, February 26th. BidaskClub lowered Dexcom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Jefferies Group lifted their price target on Dexcom from $58.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Finally, Canaccord Genuity lifted their price objective on Dexcom from $62.00 to $71.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $66.91.
In related news, insider Terrance H. Gregg sold 10,000 shares of Dexcom stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total transaction of $568,600.00. Following the sale, the insider now owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Richard Doubleday sold 2,581 shares of Dexcom stock in a transaction on Friday, March 23rd. The stock was sold at an average price of $68.44, for a total transaction of $176,643.64. Following the sale, the executive vice president now directly owns 94,429 shares in the company, valued at approximately $6,462,720.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,854 shares of company stock worth $2,141,081. 1.70% of the stock is owned by company insiders.
NASDAQ DXCM opened at $70.15 on Friday. The stock has a market cap of $6,277.71, a P/E ratio of -120.95 and a beta of -0.01. Dexcom has a 52-week low of $42.62 and a 52-week high of $81.91. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.36 and a quick ratio of 5.04.
Dexcom (NASDAQ:DXCM) last announced its earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.07. The firm had revenue of $221.00 million for the quarter, compared to analyst estimates of $217.82 million. Dexcom had a negative net margin of 6.99% and a negative return on equity of 13.99%. sell-side analysts predict that Dexcom will post -0.56 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Dexcom (DXCM) Holdings Lowered by Goldman Sachs Group Inc.” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/dexcom-inc-dxcm-stake-lessened-by-goldman-sachs-group-inc.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.